![WideCells Group PLC](https://directorstalk.net/wp-content/uploads/2017/03/WideCells-Group-PLC.png)
Pure Red Cell Aplasia and the future of treatment using stem cell therapies
What is Pure Red Cell Aplasia? Pure Red Cell Aplasia or erythroblastopenia is a form of anaemia, a blood disorder caused by a reduction in the number of red blood
What is Pure Red Cell Aplasia? Pure Red Cell Aplasia or erythroblastopenia is a form of anaemia, a blood disorder caused by a reduction in the number of red blood
Widecells Group PLC CSO Peter Hollands gives his view on new work aimed at using stem cells to create personalised drugs for treatment of mental illnesses: The article is based on
It has now been decades since stem cell technology emerged as the next great breakthrough in modern medicine, with the bold potential for one day curing everything from heart disease to cancer.
Investments that ensure the future WideCells Group’s mission is to make stem cell therapies globally accessible. The group consists of 3 divisions. CellPlan: the world’s first stem cell healthcare insurance
Professor Peter Hollands, WideCells Group Chief Scientific Officer, gives an overview of the principles of Regenerative Medicine: Regenerative Medicine is nothing new. It has been practised since the first bone
What is Non-Hodgkins Lymphoma? Non-Hodgkin’s Lymphoma is a cancer of the blood. It begins in a subset of white blood cells called lymphocytes. Lymphocytes are either B-cells (responsible for making
Widecells Group’s João Andrade discusses their agreement with Cryoviva Group to sell their stem cell insurance product, CellPlan in this exclusive interview with DirectorsTalk
Widecells Group Plc (LON:WDC) CEO João Andrade talks to DirectorsTalk about a landmark deal to launch it’s CellPlan insurance product in Asia. João explains who Cryoviva are, the impact this
WideCells Group CEO, João Andrade, said, “With over 250,000 clients, established operations in three countries and around 25,000 new samples being stored every year, this deal with Cryoviva is set to
Olivia Rezek MSc AMRSB, a Laboratory Scientist at WideCells, reviews the latest research into blood vessel cells, known as vascular endothelial cells (VECs), a subset of which are stem cells